Enliven Shares Climb on Positive Leukemia Drug Trial Data

Dow Jones

Jun 11

By Dean Seal

Enliven Therapeutics's shares jumped after the company released positive early data on the latest trial of its leukemia drug and said regulators green lit the design of a final large-scale study.

The stock was up 26% at $46.60 in premarket trading. Shares had already doubled year-to-date when the market closed Wednesday.

The clinical-stage biopharmaceutical company said before the opening bell that in the phase 1 clinical trial evaluating ELVN-001, its lead drug candidate, up to 61% of patients with previously treated chronic myeloid leukemia saw cancer markers drop significantly. Only 6% of patients stopped the treatment due to side effects.

Chief Medical Officer Helen Collins said the results were promising and showcase the consistency of ELVN-001's overall profile.

At the end of the trial, Enliven met with the Food and Drug Administration and reached an alignment with the agency on the planned daily dose and patient types to be used in a planned phase 3 trial.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

June 11, 2026 09:00 ET (13:00 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2642282119"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642282119\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642282119?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642282119","market":"nz","top_or_hot":-1,"title":"Enliven Shares Climb on Positive Leukemia Drug Trial Data","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Enliven <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>'s shares jumped after the company released positive early data on the latest trial of its leukemia drug and said regulators green lit the design of a final large-scale study. \n</p>\n<p>\n  The stock was up 26% at $46.60 in premarket trading. Shares had already doubled year-to-date when the market closed Wednesday. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said before the opening bell that in the phase 1 clinical trial evaluating ELVN-001, its lead drug candidate, up to 61% of patients with previously treated chronic myeloid leukemia saw cancer markers drop significantly. Only 6% of patients stopped the treatment due to side effects. \n</p>\n<p>\n  Chief Medical Officer Helen Collins said the results were promising and showcase the consistency of ELVN-001's overall profile. \n</p>\n<p>\n  At the end of the trial, Enliven met with the Food and Drug Administration and reached an alignment with the agency on the planned daily dose and patient types to be used in a planned phase 3 trial. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 11, 2026 09:00 ET (13:00 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enliven Shares Climb on Positive Leukemia Drug Trial Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnliven Shares Climb on Positive Leukemia Drug Trial Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-11 21:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Enliven <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>'s shares jumped after the company released positive early data on the latest trial of its leukemia drug and said regulators green lit the design of a final large-scale study. \n</p>\n<p>\n  The stock was up 26% at $46.60 in premarket trading. Shares had already doubled year-to-date when the market closed Wednesday. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said before the opening bell that in the phase 1 clinical trial evaluating ELVN-001, its lead drug candidate, up to 61% of patients with previously treated chronic myeloid leukemia saw cancer markers drop significantly. Only 6% of patients stopped the treatment due to side effects. \n</p>\n<p>\n  Chief Medical Officer Helen Collins said the results were promising and showcase the consistency of ELVN-001's overall profile. \n</p>\n<p>\n  At the end of the trial, Enliven met with the Food and Drug Administration and reached an alignment with the agency on the planned daily dose and patient types to be used in a planned phase 3 trial. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 11, 2026 09:00 ET (13:00 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2642282119","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642282119","pubTimestamp":1781182800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Enliven Therapeutics's shares jumped after the company released positive early data on the latest trial of its leukemia drug and said regulators green lit the design of a final large-scale study.The stock was up 26% at $46.60 in premarket trading. Shares had already doubled year-to-date when the market closed Wednesday.The clinical-stage biopharmaceutical company said before the opening bell that in the phase 1 clinical trial evaluating ELVN-001, its lead drug candidate, up to 61% of patients with previously treated chronic myeloid leukemia saw cancer markers drop significantly. Only 6% of patients stopped the treatment due to side effects.Chief Medical Officer Helen Collins said the results were promising and showcase the consistency of ELVN-001's overall profile.At the end of the trial, Enliven met with the Food and Drug Administration and reached an alignment with the agency on the planned daily dose and patient types to be used in a planned phase 3 trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ELVN":"Enliven Treateutics"},"translate_title":"白血病药物试验数据呈阳性，Enliven股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELVN":0.9},"content_text":"By Dean Seal \n\n\n \n\n\n  Enliven Therapeutics's shares jumped after the company released positive early data on the latest trial of its leukemia drug and said regulators green lit the design of a final large-scale study. \n\n\n  The stock was up 26% at $46.60 in premarket trading. Shares had already doubled year-to-date when the market closed Wednesday. \n\n\n  The clinical-stage biopharmaceutical company said before the opening bell that in the phase 1 clinical trial evaluating ELVN-001, its lead drug candidate, up to 61% of patients with previously treated chronic myeloid leukemia saw cancer markers drop significantly. Only 6% of patients stopped the treatment due to side effects. \n\n\n  Chief Medical Officer Helen Collins said the results were promising and showcase the consistency of ELVN-001's overall profile. \n\n\n  At the end of the trial, Enliven met with the Food and Drug Administration and reached an alignment with the agency on the planned daily dose and patient types to be used in a planned phase 3 trial. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 11, 2026 09:00 ET (13:00 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}